The Plasma Protein Therapeutics Association (PPTA) represents the manufacturers of plasma-derived and recombinant analog therapies (collectively, “plasma protein therapies”) as well as plasma donation centers who collect source plasma. These therapies are used by people worldwide to treat a variety of rare diseases and serious medical conditions. PPTA members provide about 80 percent of the plasma protein therapies for the United States market.

Some of the life-saving therapies produced by PPTA members include: clotting factors to treat bleeding disorders such as hemophilia; C1-esterase inhibitor to treat hereditary angioedema; immune globulins used to treat primary immunodeficiencies and chronic inflammatory demyelinating polyneuropathy; and alpha-1 proteinase inhibitor to treat people with alpha-1 antitrypsin deficiency.

- PPTA is committed to policies that preserve open access to all brands of plasma protein therapies in all therapeutic classes and in all sites of service.

- Plasma protein therapies are unique, non-interchangeable biological products and are not one-size-fits-all therapies. No substitutions or generics exist.

- Many plasma protein therapies are indicated exclusively to treat rare diseases or conditions as defined by the National Institutes of Health.

- Globally, there are approximately 1,000 source plasma donation centers operated by PPTA members. An average plasma center makes about 63,000 collections a year. In 2020, the industry collected more than 43 million donations in the U.S. and more than 2.9 million liters in Europe.

- PPTA and its member companies have developed voluntary industry standards for plasma collection and manufacturing that further enhance the safety and efficacy of therapies and go beyond regulations established by national and international authorities.

**PPTA Global Member Companies**

<table>
<thead>
<tr>
<th>Bio Products Laboratory</th>
<th>Biotest</th>
<th>CSL Behring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grifols</td>
<td>Kedrion SpA</td>
<td>Takeda</td>
</tr>
</tbody>
</table>

“PPTA’s voluntary standards program provides global leadership for the plasma protein industry’s goal of continuous improvement with a focus on safety and quality from the donor to the patient...”

-Mission Statement, PPTA Voluntary Standards Program